Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
26.95
+0.07 (0.26%)
At close: May 20, 2026, 4:00 PM EDT
26.42
-0.53 (-1.97%)
Pre-market: May 21, 2026, 8:57 AM EDT
Neurogene Employees
Neurogene had 131 employees as of December 31, 2025. The number of employees increased by 24 or 22.43% compared to the previous year.
Employees
131
Change (1Y)
24
Growth (1Y)
22.43%
Revenue / Employee
n/a
Profits / Employee
-$752,962
Market Cap
425.86M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 131 | 24 | 22.43% |
| Dec 31, 2024 | 107 | 16 | 17.58% |
| Dec 31, 2023 | 91 | 9 | 10.98% |
| Jun 30, 2023 | 82 | - | - |
| Dec 31, 2022 | 82 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| Replimune Group | 479 |
| 4D Molecular Therapeutics | 196 |
| ADC Therapeutics | 193 |
| Artiva Biotherapeutics | 104 |
| Assembly Biosciences | 73 |
| PureTech Health | 56 |
| Fulcrum Therapeutics | 55 |
NGNE News
- 8 days ago - Neurogene reports Q1 EPS ($1.39), consensus ($1.27) - TheFly
- 8 days ago - Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates - Business Wire
- 9 days ago - Neurogene Quarterly report: Q1 2026 - Filings
- 9 days ago - Neurogene Earnings release: Q1 2026 - Filings
- 9 days ago - Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy - Business Wire
- 10 days ago - Neurogene Slides: Corporate presentation - Filings
- 14 days ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 23 days ago - Neurogene to present on ICV delivery in CNS-targeted gene therapy - TheFly